+31 (0)6 57 27 64 27 | info@adoa.eu

👁️💙 ADOA-plus day March 29: learned a lot from Dr. Janssen and each other!

Mixed group of people sitting in a hall at tables facing a beamer with a presentation presented by Dr. Janssen. Above the footer is the text 'Successful ADOA-plus-day March'. Next to it is the Cure ADOA Foundation logo. The photo is placed on a light blue background with the familiar white eyes from the logo.

Saturday March 29th was our first meeting of 2025. This meeting focused on ADOA-plus. 

In the Business Hall we could enjoy a delicious cup of coffee or tea with something tasty before the meeting. Soon many visitors were talking to each other. The 'plus' is not common to many people, so it is nice to talk to others who may experience the same thing.

After the opening speech of the board, Dr. Janssen told us what ADOA-plus is and how it comes about. She also shared several tips. We learned, among other things, that:

👁️ The plus sign may include muscle, hearing and ataxia problems (coordination and balance), neuropathy (nerves) and fatigue.

👁️ the chance of a plus with one mutation is greater than with another.

👁️ It is best to avoid stress, smoking, harmful medications and heavy physical exertion.

👁️ The ophthalmologist and neurologist make the diagnosis.


Then there was room to ask questions. Dr. de Coo, member of our medical advisory board, was also present. Together with Dr. Janssen he answered several questions.

💙 After the informative part, people could stay to get to know each other, share experiences and learn even more from each other. 

We would like to take this opportunity to thank everyone for coming and also Dr. Janssen for her presentation!

📅 On Saturday November 1st we organize the next ADOA day. Will you be there (again)?

Research articles

During the morning program, two studies were discussed. Read the articles here:

Anesthesia for patients with neuromuscular disorders >
Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus >

Share this message via
Facebook
Twitter
LinkedIn
Email
WhatsApp